In addition to onatasertib, other dual mTOR inhibitors, such as sapanisertib (NCT02417701) and vistusertib (NCT03106155), are also undergoing clinical trials in patients with stage IV or recurrent lung cancer [201,202]. The gene discussed is MTOR; the disease is lung carcinoma.